Last update Nov. 22, 2022
Very High Risk
We do not have alternatives for Strontium-89.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Strontium-89 is also known as
Strontium-89 in other languages or writings:
Strontium-89 belongs to this group or family:
Main tradenames from several countries containing Strontium-89 in its composition:
|Protein Binding||30 - 40||%|
|VD||0.57 - 0.96||l/Kg|
Write us at firstname.lastname@example.org
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It is a radiopharmaceutical agent used for the relief of bone pain in patients with painful skeletal metastases. Intravenous administration.
Plasma strontium and strontium accumulated in bones and other tissues of the mother is excreted in breast milk. (Shagina 2015, Tolstykh 2008, Harrison 2003)
The physical elimination half-life of strontium-89 is 50.5 days. After 10 physical half-lives the element ceases to have significant radioactivity.
Given its long elimination half-life, a 505-day cessation of breastfeeding would be required to avoid irradiating the infant, expressing and discarding the milk in the meantime, making it impossible to continue breastfeeding.